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INTRODUCTION
Fibrinogen is a 340-kD glycoprotein, one of the critical
proteins of the blood coagulation and platelet aggregation
(1). It is composed of six polypeptide chains, (α , β , γ )2, which
are held together by disulfide bonds and organized in a sym-
metrical dimeric fashion (1).
Until now, a variety of mutations in each of the fibrinogen
chain genes have been reported in more than 465 families
all over the world, with Aα -chain mutation being the most
common form, followed by γ -chain mutation (2).
Several cases of congenital dysfibrinogenemia have been
reported in Korea. The first report was Aα (517-522)delins31,
designated as ‘‘fibrinogen Seoul’’ in a 7-yr-old girl associated
with amyloidosis (3). The second was γ Ala341Asp, which was
designated as ‘‘fibrinogen Seoul I’’, in a 66-yr-old woman with
peripheral artery obstructive disease (4). The third was Aα
Gln328Pro, which was designated as ‘‘fibrinogen Seoul II’’,
in a 51-yr-old man who suffered from recurrent myocardial
infarction (5). 
Here we describe a γ -chain fibrinogen variant (fibrinogen
Yecheon), which is a point mutation from T to C in the 1,007th
nucleotide of the FGG gene, resulting in a methionine (Met)-
to-threonine (Thr) substitution at the 310th residue in the
carboxy-terminal region of the fibrinogen γ -chain. This is the
fourth report of γ Met310 to Thr substitution in the world,
and the first in Korea. As for genetic dysfibrinogenemia, this
is the fourth case report in Korea. 
CASE REPORT
A 20-yr-old male patient with past medical history of bleed-
ing tendency in neonate period visited the department of
otorhinolaryngology for a preoperative evaluation for opera-
tion of chronic maxillary sinusitis. He reported a family his-
tory of easy bruisability of his father and conductive hearing
difficulty after meningitis in childhood. No laboratory abnor-
malities indicating coagulation defect had been detected after
birth. 
In the preoperative evaluation, the patient had normal blood
counts and serum chemistry test results. However, the ini-
tial coagulation screening showed prolonged prothrombin
time (PT, 24.5 sec; normal 10.4-12.5 sec) and activated par-
tial thromboplastin time (aPTT, 47.3 sec; normal, 26.0-41.0
sec). The bleeding time was normal (2 min and 30 sec; nor-
mal, 1-5 min). The PT and aPTT mixing test result indicat-
ed factor deficiency. The fibrinogen degradation product (FDP)
and d-Dimer were within normal ranges. Other coagulation
tests were normal (Table 1). On the other hand, plasma fib-
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Fibrinogen Yecheon: Congenital Dysfibrinogenemia with Gamma
Methionine-310 to Threonine Substitution
This case study reports a  rare fibrinogen variant, γ Met310Thr mutation, for the first
time in Korea. The case shows a point mutation from T to C in the 1,007th nucleotide
of the FGG gene. This report describes a variant fibrinogen, hereinafter called ‘‘fibrino-
gen Yecheon’’, using the name after the town where the patient was living at the
time of diagnosis. Fibrinogen Yecheon has a de novo heterozygous point mutation
of FGG resulting in γ Met310Thr and subsequent extra N-glycosylation at γ Asn308.
Extra N-glycosylated fibrinogen is considered a main inhibitor of normal fibrinogen
activity.
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rinogen activity of the subject examined using the Clauss
method was lower than the detection limit (<25 mg/dL; nor-
mal, 140-460 mg/dL), while the antigen level measured by
fibrinogen ELISA was normal (437 mg/dL). After a written
informed consent was obtained, a familial genetic study was
started. All exons, exon-intron boundaries, and promoter re-
gions of the fibrinogen Aα(FGA, GenBank M64982), Bβ
(FGB, GenBank M64983), and γ(FGG, GenBank M10014)
chain genes were amplified and sequenced. PCR and direct
sequencing revealed that only the patient in his family was
heterozygous for a point mutation in the FGG gene. The
mutation was a mutation substituting the 310th codon ATG
(Met) to ACG (Thr), (c.1007T>C) (Fig. 1A). He had no muta-
tions in the FGA or FGB gene. We designated the patient’s
abnormal fibrinogen as ‘‘fibrinogen Yecheon’’, naming after the
local city where he and his family are residing. Collectively,
congenital dysfibrinogenemia was identified. For further evalua-
tion, fibrinogen mixing test (Table 2) was run and the results
showed no significant improvements in the fibrinogen level.
This implies the possibility of some inhibitors of fibrinogen
activity.
The plasma fibrinogen activities of the patient’s parents by
Clauss method were within normal range (309 and 254 mg/
dL, respectively). His two elder sisters also showed normal
coagulation test results. Molecular genetic study was per-
formed only with his parents, including his father who had
a history of easy bruising, and they both were homozygous
for the wild-type allele (Fig. 1B, C). 
Test Result Reference range
FDP (μ g/mL) <10 >40 μ g/mL
D-dimer (μ g/mL) 0.45 75-150
Plasminogen (%) 130.4 75-125
Antithrombin (%) 93.4 48-151
vWF:Ag (%) >200 46-164
vWF:RCo (%) 152
Anti factor IX Ab Negative
Anti factor VIII Ab Negative
Protein C Ag (%) 113 72-160
Protein C Activity (%) 80 70-130
Protein S Ag (free) (%) 101 50-150
Factor II (%) 79 60-140
Factor V (%) 63 60-140
Factor VII (%) 90 60-140
Factor VIII (%) 87 60-140
Factor IX (%) 97 60-140
Factor X (%) 88 60-140
Factor XI (%) 108 60-140
Factor XII (%) 58 60-140
Factor XIII (%) Normal
Table 1. Coagulation test results
Sample number
Measured
(mg/dL)
Expected
(mg/dL)
Sample
type
FDP, fibrinogen degradation product; vWF, von willebrand factor; RCo,
ristocetin cofactor; Ab, antibody; Ag, antigen.
I Control I  250
II Subject NC
III I+II 13 125
IV I+III 56 187
V I+IV 100 218
VI III+VII 88 179
VII Control II 233
VIII VI+VII 99 206
Table 2. Fibrinogen mixing test
Fig. 1. The chromatogram shows DNA sequencing results of fibrinogen γ -chain gene (FGG). The A indicates the sample of the patient. A
heterozygous FGG mutation (c.1007T>C [p.Met336Thr]) was identified. The B indicates the sample of the father and the C indicates the
sample of the mother.
NC, not checkable. 
A
B
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DISCUSSION
Dysfibrinogenemia was suggested in the subject according
to the initial plasma fibrinogen activity and antigen levels.
DNA sequence analysis confirmed congenital dysfibrinogen-
emia. The patient himself decided not to take operation after
the diagnosis of dysfibrinogenemia, although cryoprecipitate
treatment was possible. Cryoprecipitate contains factor VIII,
fibrinogen, von Willebrand factor and factor XIII, so it is gen-
erally used for dysfibrinogenemia. Although he was born with
bleeding tendency, the patient had no symptoms of bleeding
or thrombosis after childhood. According to Cote et al.(1),
an examination of the clinical symptoms associated with γ -
dysfibrinogenemia shows that <5% of the individuals expe-
rienced significant bleeding, and <30% showed thrombotic
tendencies. Approximately 60% of patients with γ -dysfib-
rinogenemias were asymptomatic at the time of diagnosis.
Unfortunately, data on long-term follow-up of dysfibrino-
genemic patients are rarely available. Close observation of
clinical symptoms might be the best option for treatment.
γ Met310Thr was already reported by the names of Asahi
(6), Frankfurt VII (7), and Hannover XXIV (2). Details of
biochemical mechanisms involved in fibrin polymerization,
release of fibrinopeptides A/B, factor XIIIa-mediated cross-
linking profiles, and the position of glycosylation were elu-
cidated in the study of fibrinogen Asahi (6). Asahi fibrino-
gen showed normal release of fibrinopeptides A/B, but fib-
rin polymerization and factor XIIIa-mediated γ -chain cross-
linking were severely impaired regardless of calcium ions,
which was caused by N-glycosylation consensus sequence Asn
(308)-Gly (309)-Thr (310) conferred by the mutation (1, 6,
8). Specifically, severely impaired polymerization of Asahi fib-
rin monomers may account for extremely retarded cross-link-
ing between the two Asahi γ -chains, although the amine re-
ceptor γ Gln (398) was found to function normally (1, 6, 8).
Those functional abnormalities could explain fibrinogen Asahi
patient’s bleeding tendency as well as that of the fibrinogen
Yecheon subject, which was supported by the ultrastructure
of fibrinogen Caracas II (Aα Ser434 to N-glycosylated Asn)
detected with the use of scanning electron microscopy. In the
microscopic image, large pores bounded by local fiber net-
works made up of thin fibers were observed (9). Normally,
fibrinogen contains approximately 3% carbohydrate consist-
ing of NeuAc, Gal, Man, and GlcNAc, which is linked to
Asn 52 on the γchain and Asn 364 on the Bβchain (10). The
role of glycosylation in fibrinogen function has been studied
and its involvement in the clotting process was proposed (10),
although contradictory results have been reported (11). Steric
hindrance by the extra carbohydrate itself, the disruption of
D:D interactions by the new glycosylation, and strong neg-
ative charges of sialic acids in the extra carbohydrate could be
raised to account for disturbed fibrin polymerization or im-
paired cross-linking in Niigata (Bβ Asn160Ser), Asahi, and
Lima (Aα Arg141Ser) fibrins, respectively (1, 12-14). 
Being a heterozygote, in fibrinogen Yecheon, as in fibrino-
gen Asahi, fibrin monomer containing at least one gamma
chain mutated is not likely to function on making polymer-
ization properly. Fibrinogen mixing test results (Table 2) de-
monstrated the presence of inhibitor. FDP level was within
normal range. Those facts, therefore, suggested extra glyco-
sylated gamma chain not only dysfunction on polymeriza-
tion but also inhibit normal fibrin and fibrinogen resulting
in hardly clotting with thrombin in fibrinogen activity assay
by Clauss method. In addition, the subject’s coagulation ab-
normality was thought to be caused by extra glycosylation of
γ -chain and subsequent disruption of D:D interaction because
other coagulation factors were within normal ranges (Table 1).
The subject with fibrinogen Yecheon showed bleeding ten-
dency. Usually, dysfibrinogenemias having extra glycosylations
concerned hemorrhagic tendency unlike Tokyo V (γ Ala327-
Thr) fibrinogen which was somewhat unique in that its pro-
positus was thrombophilic partly owing to fibrinolysis-resis-
tant fibrin clots despite the very low clottability of the fibrin.
It was suggested that tissue plasminogen activator binding to
Tokyo V fibrinogen might have been affected directly. The
subject of fibrinogen Yecheon presented de novo mutation
in FGG, while his parents did not show any coagulation ab-
normalities including DNA sequencing. De novo mutations
are associated with advancing paternal age (15) and pollutants
(16, 17). 
One thing different between Yecheon and Asahi subjects
was the level of FDP, which was normal (2.3 μ g/mL) for the
Yecheon subject while that was markedly increased to 160 μ g/
mL for the Asahi patient. Because d-dimer level was within
normal range, the Yecheon subject was not considered in the
state of hyperfibrinolysis, which was partially supported by
the normal levels of plasminogen and antithrombin. As a
follow-up, a further study can be conducted to understand
what brought about marked increase in FDP level for Asahi
subject.
Fibrinogen Yecheon is the only congenital dysfibrinogen-
emia in Korea associated with bleeding tendency, and not
thrombosis or amyloidosis. Our subject was born with bleed-
ing tendency, although he had no history of serious bleeding
symptoms. In general, mutations within the γchain of fib-
rinogen are not associated with serious bleeding disorders.
Two patients, Baltimore I (Gly292Val) and Giessen IV (Asp-
318Gly), who experienced mild bleeding symptoms, also suf-
fered from thrombotic tendencies. The only γ -dysfibrinogen-
emia associated with a serious bleeding diathesis is Asahi I
(Met310Thr). In this instance, the bleeding symptoms were
probably related to the extra glycosylation resulting from the
substitution (1).
In conclusion, this report describes a variant fibrinogen, here-
inafter called ‘‘fibrinogen Yecheon’’, using the name after the
town where the patient was living at the time of diagnosis
(2). Fibrinogen Yecheon has a de novo heterozygous point
mutation of FGG resulting in γ Met310Thr and subsequent1206 E. Park, G. Park, R. Park, et al.
extra N-glycosylation at γ Asn308. Extra N-glycosylated fib-
rinogen is considered a main inhibitor of normal fibrinogen
activity. 
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